CORDIS
EU research results

CORDIS

English EN

Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases

Project information

Grant agreement ID: 260895

Status

Closed project

  • Start date

    1 October 2010

  • End date

    31 March 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 862 161,80

  • EU contribution

    € 5 991 600

Coordinated by:

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

Objective

Chronic inflammatory diseases associated with allergy, including asthma and rhinitis, constitute a major and continuously growing public health concern for Europe. However, the causative factors and mechanisms converting a physiological inflammatory reaction to a chronic response triggering allergic disease remain elusive.
Viral infections, particularly those caused by human rhinoviruses (RV) are the most frequent triggers of acute asthma exacerbations. RV infections have more recently been associated with asthma initiation; there is evidence suggesting that such infections may also contribute to respiratory allergy persistence.
The strategic aims of PreDicta are to evaluate the hypothesis that repeated infections reprogram the immune system towards a persistent inflammatory pattern leading to respiratory allergies by (i) dissecting the molecular and cellular mechanisms involved in the lack of resolution of inflammation in the context of a human disease, (ii) identifying specific infectious agents and underlying altered host-pathogen interactions, and develop relevant prognostic and therapeutic strategies. PreDicta follows three interconnected workflows: models, mechanisms and translational output. Models include a longitudinal cohort in children, mouse models of repeated virus infection, primary epithelial cultures from patients, viral-bacterial interaction models, and models of epithelial-T-cell-dendritic cell interactions. These will be used to look into disease persistence, inflammation patterns, dysbiosis, immune regulation and resolution of inflammation. Translational outputs include prognostic use of subtype-specific antiviral antibodies, DNAZymes for therapeutic use and delivery technologies targeted to the bronchial epithelium.
This interdisciplinary Consortium with strong track record, unique resources and strong translational focus, aims to produce new knowledge and technologies that can rapidly and effectively reach clinical care.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Address

6 Christou Lada Str
10561 Athina

Greece

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 560 077

Administrative Contact

Efstathia Kafentzi (Ms.)

Participants (12)

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 1 080 780

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 644 400

SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS

Switzerland

EU Contribution

€ 640 955

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 582 972

UNIVERSYTET MEDYCZNY W LODZI.

Poland

EU Contribution

€ 249 910

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 589 020

PHILIPPS UNIVERSITAET MARBURG

Germany

EU Contribution

€ 489 180

TURUN YLIOPISTO

Finland

EU Contribution

€ 210 420

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 403 676

BIOMAY AG

Austria

EU Contribution

€ 77 250

INSERM TRANSFERT SA

France

EU Contribution

€ 300 000

VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA

Finland

EU Contribution

€ 162 960

Project information

Grant agreement ID: 260895

Status

Closed project

  • Start date

    1 October 2010

  • End date

    31 March 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 862 161,80

  • EU contribution

    € 5 991 600

Coordinated by:

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece